Brief: HUTCHMED (China) Announces NMPA Conditional Approval For Orpathys For Met-Amplified Advanced Gastric Cancer In China
02/07/2026 10:44
BRIEF-HUTCHMED (China) Announces NMPA Conditional Approval For Orpathys For Met-Amplified Advanced Gastric Cancer In China July 2 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
ANNOUNCES NMPA CONDITIONAL APPROVAL FOR ORPATHYS FOR MET-AMPLIFIED ADVANCED GASTRIC CANCER IN CHINA
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsKras: EGFR-Antibody licensing deal with GSK closes
Brief: Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals
Factbox: Major drugmakers turn to China for licensing deals